Abstract
Introduction Following its emergence in January 2020, SARS-CoV-2 diffusion occurred for a year with only non-pharmaceutical interventions (NPIs) available as mitigation tools. We aimed to assess the predictive capability of census-based indicators on the infection risk by SARS-CoV-2 in the French Auvergne-Rhône-Alpes region to assist NPIs allocation at the neighbourhood level.
Methods We aggregated all counts of biologically confirmed cases of SARS-CoV-2 infection at the neighbourhood level between May 2020 and February 2021. 10 census-based ecological covariates were evaluated as predictors of case incidence using a Poisson regression with conditional autoregressive (CAR) spatial effects. Benefits of CAR effects and covariates on model fit were evaluated using pseudo-R² and Moran’s I statistics.
Results 438,992 infection cases over 5,410 neighbourhoods among 7,917,997 inhabitants were analysed. The association between covariates and case incidence was inconstant across time and space. Spatial correlation was estimated at high levels. Spatial CAR effects were necessary to improve on the pseudo-R2 and the Moran’s I statistics compared to the null model (intercept only).
Conclusion The ecological covariates assessed were insufficient to adequately model the distribution of cases at the neighbourhood level. Excess incidence was found mainly in metropolitan areas before the epidemic wave peak.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data accessibility
The infection cases data that support the findings of this study are available from the French Health Data Hub within the SI-DEP database. Restrictions apply to the availability of these data, which were used under licence for this study. Data may be requested by the following procedure: https://www.demarches-simplifiees.fr/commencer/soumission-d-un-projet-de-recherche-etude-ou-evalu.
The census data that support the findings of this study are openly available on the INSEE website at the following links: https://www.insee.fr/fr/statistiques/4799268, https://www.insee.fr/fr/statistiques/4799323, https://www.insee.fr/fr/statistiques/4799252, https://www.insee.fr/fr/statistiques/4799305.
The administrative layout data that support the findings of this study are openly available on the INSEE website at the following link: https://www.insee.fr/fr/information/2017499
The geographical data that support the findings of this study are openly available on the Geofabrik website at the following links: https://download.geofabrik.de/europe/france.html
Codes and specific datasets (with the exception of the infection cases dataset) are available on request to the corresponding author.
